Assoc.Prof. Dr. Didem DAYANGAÇ
Transkript
Assoc.Prof. Dr. Didem DAYANGAÇ
Didem Dayangaç-Erden, PhD. e-mail: didayan (@) hacettepe.edu.tr Tel: 0 312 305 2541 Eğitim: 1999-2005: Hacettepe University Medical Faculty Department of Medical Biology (Ph.D.) 1997-1999: Hacettepe University Medical Faculty Department of Medical Biology (M.Sc.) 1993-1997: Hacettepe University Faculty of Science Department of Biology, BSc Academic Experience: 2013- Hacettepe University Faculty of Medicine Department of Medical Biology, Assoc..Prof. 2010- 2013 Hacettepe University Faculty of Medicine Department of Medical Biology, Assist.Prof. 2006- 2009 Hacettepe University Faculty of Medicine Department of Medical Biology, lecturer Aug.- Oct. 2001: Medical School Hannover, Department of Biochemistry and Tumour Biology, Hannover, Germany; Molecular genetic analysis in CBAVD patients June- August 2003: Medical School Hannover, Department of Biochemistry and Tumour Biology, Hannover, Germany, CFTR sequencing, transcript and protein analysis, Sept. - Dec. 2004: Istituto di Genetica Medica, Universita Cattolica, Rome, Italy. The effect of histone deacetylase inhibitors on SMN gene expression in SMA patients 1999- 2005 : Hacettepe University Faculty of Medicine Department of Medical Biology, Research Assistant Research Areas: identification of modifier genes and responsible pathways in spinal muscular atrophy, genotypephenotype correlation, transcriptome analysis, identification of biomarker candidates and novel therapeutic targets. Selected Projects: 1. 2015- ongoing. TUBİTAK 3001, 114S914, “The investigation of the function of perineuronal net elements in spinal muscular atrophy pathogenesis”, Project Coordinator 2. 2013- ongoing. H.Ü, 946, “The investigation of the role of HAPLN1 in the neurite outgrowth”, Project Coordinator 3. 2011- 2013. H.Ü. 011D01101010 “Investigation of modifying effect of plastin3 gene on spinal muscular atrophy patients phenotype”, Project Coordinator 4. 2006-2009. TUBITAK KAMAG, 105G014 "Investigation of potential drug candidate compounds in hereditary diseases caused by RNA splicing defects”, Researcher 5. 2003- 2005. H.Ü 03G014, “Designing new vector casettes for gene therapy and biotechnologic areas”, Researcher 6. 2002- 2005. TÜBİTAK SBAG-2599, “The investigation of the role of sodium butyrate on the treatment of spinal muscular atrophy RNA splicing defects”, Researcher 7. 1998-2000. H.U.B.A.B 9802101004, “Prenatal diagnosis in Spinal Muscular Atrophy”, Researcher Scientific Committees Memberships: Association of Medical Biology and Genetics Turkish Biochemical Society Scientific Awards: CF European Network, 2001, Cystic Fibrosis European Network Scholarship Prof. Dr. Altan Günalp Scientific Award (2009): Histone deacetylase inhibition activity and molecular docking of (e )-resveratrol: its therapeutic potential in spinal muscular atrophy. Chem Biol Drug Des. 2009 Mar;73(3):355-64. XI. National Congress of Medical Biology and Genetics, 28-31 October 2009, Bodrum, Muğla Selected Publications: 1. Uzunallı G, Bora-Tatar G, Dayangaç-Erden D, Erdem-Yurter H. Effects of flavonoid quercetin on survival of motor neuron gene expression. Cell Biol Int. 2015 Mar; 39 (3): 350-4. 2. Yener İ.H, Dayangaç-Erden D. Tek Gen Hastalıklarında Fenotipi Modifiye Eden Genlerin Rolü. Marmara Med J. 2014, 27: 96-101. 3. Ayhan Eşiyok P, Seven Ö, Eymur G, Bora Tatar G, Dayangac Erden D, Yelekçi K, Yurter H, Demir AS. Aryl butenoic acid derivatives as a new class of histone deacetylase inhibitors: synthesis, in vitro evaluation, and molecular docking studies. Turk. J. Chem. 2014, 38:338-344. 4. Dayangaç-Erden D, Bora-Tatar G, Dalkara S, Demir AS, Erdem-Yurter H. Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: A promising target for spinal muscular atrophy therapeutics. Arch Med Sci, 2011, 7, (2): 230-234. 5. Ozaydin E, Dayangac-Erden D, Erdem-Yurter H, Derman O, Coşkun T. The relationship between vitamin D receptor gene polymorphisms and bone density, osteocalcin level and growth in adolescents. J Pediatr Endocrinol Metab., 2010, 23, (5): 491-496. 6. Durusu Tanriover M, Bora Tatar G, Uluturk TD, Dayangac Erden D, Tanriover A, Kilicarslan A, Oz SG, Erdem Yurter H, Sozen T, Sain Guven G. Evaluation of the effects of vitamin D receptor and estrogen receptor 1 gene polymorphisms on bone mineral density in postmenopausal women. Clin Rheumatol. 2010, 29, (11): 1285-1293. 7. Havasi V, Rowe SM, Kolettis PN, Dayangac D, Sahin A, Grangeia A, Carvalho F, Barros A, Sousa M, Bassas L, Casals T, Sorscher EJ. Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferens. Fertil Steril. 2010, 94, (6): 2122-2127. 8. Dayangaç-Erden D, Bora G, Ayhan P, Kocaefe C, Dalkara S, Yelekçi K, Demir AS, ErdemYurter H. Histone deacetylase inhibition activity and molecular docking of (E)resveratrol: its therapeutic potential in spinal muscular atrophy. Chem Biol Drug Des., 2009, 73 (3): 355-364. 9. Bora-Tatar G, Dayangaç-Erden D, Demir AS, Dalkara S, Yelekçi K, , Erdem-Yurter H. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. Bioorg Med Chem. 2009, 17 (14): 5219- 5228.